Skip to main content

Advertisement

SpringerLink
Log in

Diagnostic performance of Mac-2-binding protein glycosylation isomer (M2BPGi) as a liver fibrosis marker in chronic hepatitis C patients with chronic kidney disease on hemodialysis

  • Original article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Background/aim

Liver fibrosis assessment is essential to determine the initiation, duration, and evaluation of chronic hepatitis C treatment. Therefore, the study aimed to assess the role of Mac-2-binding protein glycosylation isomer (M2BPGi) as a biomarker to measure liver fibrosis in chronic hepatitis C patients with chronic kidney disease on hemodialysis.

Methods

This study used a cross-sectional design. Serum M2BPGi level and transient elastography results were evaluated in 102 chronic hepatitis C patients with CKD on HD, 36 CKD on HD patients, and 48 healthy controls. ROC analysis was conducted to identify the optimal cutoff values to assess significant fibrosis and cirrhosis among chronic hepatitis C patients with CKD on HD.

Results

In chronic hepatitis C patients with CKD on HD, the level of serum M2BPGi had a moderately significant correlation with transient elastography (r = 0.447, p < 0.001). The median serum M2BPGi was higher among CKD on HD patients compared to healthy controls (1.260 COI vs. 0.590 COI, p < 0.001) and was even higher in chronic hepatitis C patients with CKD on HD compared to CKD on HD group (2.190 COI vs. 1.260 COI, p < 0.001). It is also increased according to the severity of liver fibrosis: 1.670 COI, 2.020 COI, and 5.065 COI for F0–F1, significant fibrosis, and cirrhosis, respectively. The optimal cutoff values for diagnosing significant fibrosis and cirrhosis were 2.080 and 2.475 COI, respectively.

Conclusion

Serum M2BPGi could be a simple and reliable diagnostic tool for evaluating cirrhosis in chronic hepatitis C patients with CKD on HD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

The dataset generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.

References

  1. World Health Organization. Hepatitis C. In WHO; 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c

  2. Republic of Indonesia Ministry of Health. Basic Health Research Report. Indonesian Ministry of Health, Jakarta. 2013.

  3. Hill NR, Fatoba ST, Oke JL, Hirst JA, Christopher OCallaghan A, et al. Global prevalence of chronic kidney disease—a systematic review and meta-analysis. PLoS ONE. 2016;5:103–16.

    Google Scholar 

  4. Perhimpunan Peneliti Hati Indonesia. Konsensus Nasional Penatalaksanaan Hepatitis C pada penyakit Ginjal Kronik di Indonesia. Jakarta. 2019.

  5. Humphreys BD. Mechanisms of renal fibrosis. Annu Rev Physiol. 2017;80(1):309–26.

    Article  PubMed  Google Scholar 

  6. Kim AJ, Lim HJ, Ro H, Jung JY, Lee HH, Chung W, et al. Liver cirrhosis leads to poorer survival in patients with end-stage renal disease. Korean J Intern Med. 2016;31(4):730–8.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Cacoub P, Desbois AC, Isnard-Bagnis C, Rocatello D, Ferri C. Hepatitis C virus infection and chronic kidney disease: time for reappraisal. J Hepatol [Internet]. 2016;65(1):S82-94. https://doi.org/10.1016/j.jhep.2016.06.011.

    Article  PubMed  Google Scholar 

  8. Khan MU, Mahmoud MI, Butt AA. Hepatitis c virus and chronic kidney disease. Expert Rev Gastroenterol Hepatol [Internet]. 2020;00(00):579–90. https://doi.org/10.1080/17474124.2020.1776111.

    Article  CAS  Google Scholar 

  9. Widhani A, Lydia A, Gani RA, Setiati S. Serokonversi Hepatitis C pada Pasien Hemodialisis di Rumah Sakit Cipto Mangunkusumo. J Penyakit Dalam Indones. 2017;2(1):15.

    Article  Google Scholar 

  10. Cavalcanti Sette LHB, de LopesA EP. Liver enzymes serum levels in patients with chronic kidney disease on hemodialysis: a comprehensive review. Clinics. 2014;69(4):271–8.

    Article  Google Scholar 

  11. Park H, Adeyemi A, Henry L, Stepanova M, Younossi ZM. A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. J Viral Hepat. 2015;22(11):897–905.

    Article  CAS  PubMed  Google Scholar 

  12. Alpers CE, Smith KD. Cryoglobulinemia and renal disease. Curr Opin Nephrol Hypertens. 2008;17(3):243–9.

    Article  PubMed  Google Scholar 

  13. Hsu YH, Hung PH, Muo CH, Tsai WC, Hsu CC, Kao CH. Interferon-based treatment of hepatitis C virus infection reduces all-cause mortality in patients with end-stage renal disease an 8-year nationwide cohort study in Taiwan. Med (United States). 2015;94(47):e2113.

    CAS  Google Scholar 

  14. Fabrizi F, Martin P, Dixit V, Messa P. Meta-analysis of observational studies: hepatitis C and survival after renal transplant. J Viral Hepat. 2014;21(5):314–24.

    Article  CAS  PubMed  Google Scholar 

  15. Indonesian Ministry of Health (2020) Policy and epidemiological situation of hepatitis and gastrointestinal infectious diseases in Indonesia.

  16. Chi H, Hansen BE, Tang WY, Schouten JNL, Sprengers D, Taimr P, et al. Multiple biopsy passes and the risk of complications of percutaneous liver biopsy. Eur J Gastroenterol Hepatol. 2017;29(1):36–41.

    Article  PubMed  Google Scholar 

  17. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97(10):2614–8.

    Article  PubMed  Google Scholar 

  18. Mendes L, Stucchi R, Vigani A. Diagnosis and staging of fibrosis in patients with chronic hepatitis C: comparison and critical overview of current strategies. Hepatic Med Evid Res. 2018;10:13–22.

    Article  Google Scholar 

  19. Agbim U, Asrani SK. Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers. Expert Rev Gastroenterol Hepatol [Internet]. 2019;13(4):361–74. https://doi.org/10.1080/17474124.2019.1579641.

    Article  CAS  PubMed  Google Scholar 

  20. Khunpakdee N, Jayanama K, Kaewdoung P, Promson K, Rattanasiri S, Warodomwichit D, et al. Transient elastography in end-stage renal disease patients on hemodialysis: the effect of net fluid withdrawal. Blood Purif. 2015;40(3):256–9.

    Article  PubMed  Google Scholar 

  21. Liu CH, Liang CC, Huang KW, Liu CJ, Chen SI, Lin JW, et al. Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients. Clin J Am Soc Nephrol. 2011;6(5):1057–64.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Shirabe K, Bekki Y, Gantumur D, Araki K, Ishii N, Kuno A, et al. Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis. J Gastroenterol [Internet]. 2018;53(7):819–26. https://doi.org/10.1007/s00535-017-1425-z.

    Article  CAS  PubMed  Google Scholar 

  23. Ito K, Murotani K, Nakade Y, Inoue T, Nakao H, Sumida Y, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels and liver fibrosis: a meta-analysis. J Gastroenterol Hepatol. 2017;32(12):1922–30.

    Article  CAS  PubMed  Google Scholar 

  24. Nishikawa H, Enomoto H, Iwata Y, Hasegawa K, Nakano C, Takata R, et al. Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level and high-sensitivity C-reactive protein concentration in autoimmune hepatitis. Hepatol Res. 2016;46(7):613–21.

    Article  CAS  PubMed  Google Scholar 

  25. Yamada N, Sanada Y, Tashiro M, Hirata Y, Okada N, Ihara Y, et al. Serum Mac-2 binding protein glycosylation isomer predicts grade F4 liver fibrosis in patients with biliary atresia. J Gastroenterol. 2017;52(2):245–52.

    Article  CAS  PubMed  Google Scholar 

  26. Umemura T, Joshita S, Sekiguchi T, Usami Y, Shibata S, Kimura T, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis. Am J Gastroenterol [Internet]. 2015;110(6):857–64. https://doi.org/10.1038/ajg.2015.118.

    Article  CAS  PubMed  Google Scholar 

  27. Abe M, Miyake T, Kuno A, Imai Y, Sawai Y, Hino K, et al. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol. 2015;50(7):776–84.

    Article  CAS  PubMed  Google Scholar 

  28. Xu H, Kong W, Liu L, Chi X, Wang X, Wu R, et al. Accuracy of M2BPGi, compared with Fibro Scan®, in analysis of liver fibrosis in patients with hepatitis C. BMC Gastroenterol. 2017;17(1):1–7.

    Article  Google Scholar 

  29. Mak LY, Wong DKH, Seto WK, Ning Q, Cheung KS, Fung J, et al. Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection. Hepatol Int [Internet]. 2019;13(2):148–56. https://doi.org/10.1007/s12072-019-09928-5.

    Article  PubMed  Google Scholar 

  30. Imanaka S, Shibasakiy Y. A study of Mac-2 binding protein glycosylation isomer (M2BPGi), a serum marker of liver fibrosis, in patients undergoing maintenance hemodialysis. Ther Res. 2019;40(4):323–7.

    Google Scholar 

  31. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol. 2008;172(2):288–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Schmoyer CJ, Kumar D, Gupta G, Sterling RK. Diagnostic accuracy of noninvasive tests to detect advanced hepatic fibrosis in patients with hepatitis c and end-stage renal disease. Clin Gastroenterol Hepatol [Internet]. 2020;18(10):2332–9. https://doi.org/10.1016/j.cgh.2020.02.019.

    Article  CAS  PubMed  Google Scholar 

  33. Ghany MG, Morgan TR. Hepatitis C Guidance 2019 update: American association for the study of liver diseases-infectious diseases society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020;71(2):686–721.

    Article  PubMed  Google Scholar 

  34. Lee JJ, Wei YJ, Lin MY, Niu SW, Hsu PY, Huang JC, et al. The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C. PLoS One [Internet]. 2020;15(11):1–12. https://doi.org/10.1371/journal.pone.0242601.

    Article  CAS  Google Scholar 

  35. Taneja S, Borkakoty A, Rathi S, Kumar V, Duseja A, Dhiman RK, et al. Assessment of liver fibrosis by transient elastography should be done after hemodialysis in end stage renal disease patients with liver disease. Dig Dis Sci. 2017;62(11):3186–92.

    Article  PubMed  Google Scholar 

  36. Waragai Y, Suzuki R, Takagi T, Sugimoto M, Asama H, Watanabe K, et al. Clinical significance of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in pancreatic ductal adenocarcinoma. Pancreatology [Internet]. 2016;16(6):1044–50. https://doi.org/10.1016/j.pan.2016.09.003.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The author would like to thank the National Institute of Health Research and Development, the Indonesian Ministry of Health, and Sysmex Indonesia for funding the study. Moreover, the author would also extend their gratitude to Raysha Afiff, Pertiwi Puji Lestari, and Dwi Handayu (Hepatobiliary Division, Faculty of Medicine Universitas Indonesia) for their excellent technical assistance on sample collection and processing.

Funding

Ministry of Health of the Republic of Indonesia, HK.03.01/1/994/2020, Andri Sanityoso Sulaiman.

Author information

Authors and Affiliations

  1. Hepatobiliary Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia

    Andri Sanityoso Sulaiman, Irsan Hasan, Rachmadianti Sukma Hanifa & Rino Alvani Gani

  2. Nephrology and Hypertension Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia

    Ni Made Hustrini & Aida Lydia

Authors
  1. Andri Sanityoso Sulaiman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Irsan Hasan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ni Made Hustrini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aida Lydia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rachmadianti Sukma Hanifa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rino Alvani Gani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andri Sanityoso Sulaiman.

Ethics declarations

Conflict of interest

Andri Sanityoso Sulaiman received research grant from the Ministry of Health of the Republic of Indonesia and Sysmex Indonesia company. The other authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sulaiman, A.S., Hasan, I., Hustrini, N.M. et al. Diagnostic performance of Mac-2-binding protein glycosylation isomer (M2BPGi) as a liver fibrosis marker in chronic hepatitis C patients with chronic kidney disease on hemodialysis. Clin Exp Nephrol 27, 557–564 (2023). https://doi.org/10.1007/s10157-023-02319-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-023-02319-z

Keywords

Search

Navigation